NCT00044889已完成2 期
A Phase II, Open-Label Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Genzyme, a Sanofi Company12 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2002年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 12
研究概览
简要总结
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.
This is a single arm, open-label, Phase II study of CLOFARABINE in adult patients with refractory or relapsed acute myelogenous leukemia (AML). Qualified patients must be refractory to one or two induction regimens, or have relapsed < one year from the date of confirmation of the initial complete remission (CR). There will be two phases in this study - an Induction phase and a Consolidation phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •note: For inclusion and
排除标准
- •, a regimen is defined as including Induction, Consolidation, and Maintenance therapies.
- •Diagnosis of AML according to FAB classification
- •Must not be eligible for therapy of higher curative potential, and must be in first or subsequent relapse and/or refractory
- •A Karnofsky Performance Status (KPS) of greater than or equal to
- •If female of childbearing potential, patients must have a negative serum or urine pregnancy test within 7 days of study enrollment. Men and women with reproductive potential must use as an effective contraceptive method while enrolled in the study. Patients must have contraceptive and/or fertility counseling prior to entering the study, i.e., information on sperm banking, etc.
- •Signed, written informed consent.
- •Ability to comply with study procedures and follow-up examinations.
- •Adequate organ function as indicated by specific laboratory values (defined in the protocol), obtained within two weeks prior to registration.
- •Classified as AML FAB M3 (Acute Promyelocytic leukemia) and have been treated with at least 2 regimens (a retinoic acid containing regimen and an arsenic trioxide containing regimen) before being considered for this study.
- •Exclusion Criteria:
- •note: For inclusion and exclusion criteria, a regimen is defined as including Induction, Consolidation, and Maintenance therapies.
- •Received previous treatment with CLOFARABINE.
- •Received more than two previous induction regimens or cycles for the treatment of AML.
- •Relapsed > 1 year.
- •Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
- •Are pregnant or lactating.
- •Have psychiatric disorders that would interfere with consent, study participation or follow-up.
- •Are receiving any other chemotherapy or corticosteroids. Patients must be off previous therapy for at least two weeks and must have recovered from acute toxicity of all previous therapy prior to enrollment.
- •Have any other severe concurrent disease.
- •Have symptomatic CNS involvement.
- •Have chronic myelogenous leukemia (CML) in lymphoid blast crisis).
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) PatientsLeukemia, Myelocytic, Acute, PediatricNCT00042354Genzyme, a Sanofi Company40
已完成
2 期
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)Leukemia, Lymphoblastic, Acute, PediatricNCT00042341Genzyme, a Sanofi Company60
已完成
1 期
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.Acute Myelogenous LeukemiaRelapsed LeukemiaAcute Lymphoblastic LeukemiaNCT00315705Genzyme, a Sanofi Company50
已完成
2 期
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)Acute Myelogenous LeukemiaAcute Myeloid LeukemiaNCT00373529Genzyme, a Sanofi Company116
已完成
1 期
Clofarabine in Adult Patients With Advanced Solid TumorsSolid TumorsLeukemia, Lymphocytic, Acute, PediatricLeukemia, Lymphocytic, Acute, AdultLeukemia, Myelocytic, Acute, PediatricLeukemia, Myelocytic, Acute, AdultMyelodysplastic Syndromes, AdultNCT00125840Genzyme, a Sanofi Company